| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 01/21/2014 | CA2570990C Expression-enhanced polypeptides |
| 01/21/2014 | CA2561405C Monoclonal antibodies to gastrin hormone |
| 01/21/2014 | CA2559144C Estrogen receptor alpha splice variant er-.alpha.36 |
| 01/21/2014 | CA2495177C Novel n-acetylgalactosamine transferases and nucleic acids encoding the same |
| 01/21/2014 | CA2478047C Rs7 antibodies |
| 01/21/2014 | CA2446723C Antibodies that immunospecifically bind to trail receptors |
| 01/21/2014 | CA2418014C Immunotherapy for chronic myelocytic leukemia |
| 01/21/2014 | CA2388477C Recombinant gelatins with uniform molecular weight |
| 01/21/2014 | CA2341763C Antigenic peptides of aglyco 10b and antibodies thereto |
| 01/16/2014 | WO2014012085A2 Bispecific asymmetric heterodimers comprising anti-cd3 constructs |
| 01/16/2014 | WO2014012082A2 Multivalent heteromultimer scaffold design an constructs |
| 01/16/2014 | WO2014012007A2 Rspo3 binding agents and uses thereof |
| 01/16/2014 | WO2014011955A2 Il-1 binding proteins |
| 01/16/2014 | WO2014010813A1 Adsorption column for antibody purification using fc binding peptide of antibody |
| 01/16/2014 | WO2014010758A1 Anti-tumour agent, marker for tumour detection, and oral vaccine agent |
| 01/16/2014 | WO2014010232A1 Ly6k epitope peptides for th1 cells and vaccines containing the same |
| 01/16/2014 | WO2014010231A1 Kif20a epitope peptides for th1 cells and vaccines containing the same |
| 01/16/2014 | WO2014010229A1 Cdca1 epitope peptides for th1 cells and vaccines containing the same |
| 01/16/2014 | WO2014009707A1 Variant ige fc regions |
| 01/16/2014 | WO2014009465A1 Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
| 01/16/2014 | WO2014009358A1 Anti-dr5 family antibodies, bispecific or multivalent anti-dr5 family antibodies and methods of use thereof |
| 01/16/2014 | WO2013177035A3 Humaneered anti-factor b antibody |
| 01/16/2014 | US20140020125 Methods of Modifying Eukaryotic Cells |
| 01/16/2014 | US20140020124 Methods of Modifying Eukaryotic Cells |
| 01/16/2014 | US20140018523 Protein purification |
| 01/16/2014 | US20140018522 Methods of Modifying Eukaryotic Cells |
| 01/16/2014 | US20140018521 Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv) |
| 01/16/2014 | US20140018261 Focused libraries of genetic packages |
| 01/16/2014 | US20140017782 Methods for Modifying Eukaryotic Cells |
| 01/16/2014 | US20140017781 Methods of Modifying Eukaryotic Cells |
| 01/16/2014 | US20140017774 Pca3, pca3 genes, and methods of use |
| 01/16/2014 | US20140017727 Cna-B DOMAIN ANTIGENS IN VACCINES AGAINST GRAM POSITIVE BACTERIA |
| 01/16/2014 | US20140017266 Anti-podoplanin antibodies and methods of use |
| 01/16/2014 | US20140017258 Compositions against bacterial toxins |
| 01/16/2014 | US20140017257 IgY From Norovirus P Particles And Their Derivatives |
| 01/16/2014 | US20140017256 Crystalline anti-human il-12 antibodies |
| 01/16/2014 | US20140017255 Fully human antibodies to btla |
| 01/16/2014 | US20140017253 RSPO3 Binding Agents and Uses Thereof |
| 01/16/2014 | US20140017252 Binding epitopes for g250 antibody |
| 01/16/2014 | US20140017250 Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases |
| 01/16/2014 | US20140017249 Methods for improvement of beta cell function |
| 01/16/2014 | US20140017248 Interleukin-10 peptides and antibodies thereof for inhibiting adverse effects of protozoan infection |
| 01/16/2014 | US20140017246 Il-17 binding proteins |
| 01/16/2014 | US20140017244 Bispecific Anti-VEGF/Anti-ANG-2 Antibodies and their use in the Treatment of Ocular Vascular Diseases |
| 01/16/2014 | US20140017243 Use of adcc-optimized antibodies for treating weak patients |
| 01/16/2014 | US20140017242 Anti-bradykinin b2 receptor (bkb2r) monoclonal antibody |
| 01/16/2014 | US20140017241 Non-natural ribonuclease conjugates as cytotoxic agents |
| 01/16/2014 | US20140017238 Methods of Modifying Eukaryotic Cells |
| 01/16/2014 | US20140017237 BCR-Complex-Specific Antibodies and Methods of Using Same |
| 01/16/2014 | US20140017236 Methods for treating interleukin-6 related diseases |
| 01/16/2014 | US20140017234 Antibodies targeting hiv escape mutants |
| 01/16/2014 | US20140017229 Methods of Modifying Eukaryotic Cells |
| 01/16/2014 | US20140017197 Anti-CD19 Antibodies |
| 01/16/2014 | US20140017167 Anti-IL1RAP Antibodies and Their Use for Treating Human |
| 01/16/2014 | US20140017166 Material and methods for treating or preventing her-3 associated diseases |
| 01/16/2014 | CA2876730A1 Enhancing activity of car t cells by co-introducing a bispecific antibody |
| 01/15/2014 | EP2685238A2 Method to screen high affinity antibody |
| 01/15/2014 | EP2684896A1 Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof |
| 01/15/2014 | EP2684895A1 Crystalline anti-hTNFalpha antibodies |
| 01/15/2014 | EP2684889A2 Multivariable antigens complexed with targeting humanized monoclonal antibody |
| 01/15/2014 | EP2683741A2 Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
| 01/15/2014 | EP2683740A2 Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution |
| 01/15/2014 | EP2683739A1 Humanised anti ctla-4 antibodies |
| 01/15/2014 | EP2683738A1 Anti oligomer antibodies and uses thereof |
| 01/15/2014 | EP2683737A1 Extracellular targeted drug conjugates |
| 01/15/2014 | EP2683736A1 Methods and reagents for creating monoclonal antibodies |
| 01/15/2014 | EP2683735A1 Bispecific three-chain antibody-like molecules |
| 01/15/2014 | EP2683406A2 Anti-cd40 antibodies and uses thereof |
| 01/15/2014 | EP2683404A1 The method of treating amyotrophic lateral sclerosis |
| 01/15/2014 | EP2683397A1 Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
| 01/15/2014 | EP2683396A1 Factor xii inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
| 01/15/2014 | EP2683362A2 Protein nanoparticle dispersions |
| 01/15/2014 | EP2282773B1 Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| 01/15/2014 | EP1037926B1 TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 01/15/2014 | CN103517922A Antibodies directed against ICOS and uses thereof |
| 01/15/2014 | CN103517921A IL-1-alpha and -beta duplex-specific and dual variable domain immunoglobulins and uses thereof |
| 01/15/2014 | CN103517920A Anti - sclerostin antibody crystals and formulations thereof |
| 01/15/2014 | CN103517918A Antagonistic DR3 ligands |
| 01/15/2014 | CN103509760A Hybridoma cell capable of secreting anti-beta2-microglobulin monoclonal antibody, and application thereof |
| 01/15/2014 | CN103509759A Anti-IHNV (Infectious Hematopoietic Necrosis Virus) monoclonal antibody 5H3 and application thereof |
| 01/15/2014 | CN103509758A Anti-SVCV (Spring Viraemia of Carp Virus) monoclonal antibody 3E1 as well as preparation and application thereof |
| 01/15/2014 | CN103509757A Hybridoma cell strain No. 15, and pyrethroid-resistant mass selection monoclonal antibody produced by hybridoma cell strain No. 15 |
| 01/15/2014 | CN103509756A Mycoplasma bovis monoclonal antibody, and preparation method and application thereof |
| 01/15/2014 | CN103509117A Bispecific antibody capable of resisting human epidermal growth factor receptor 2 (HER2) and human insulin-like growth factor-IR (IGF-IR), and preparation method and applications thereof |
| 01/15/2014 | CN103509116A 抗体纯化 Antibody Purification |
| 01/15/2014 | CN103509115A Nanometer antibodies to human cystatin C and application thereof |
| 01/15/2014 | CN103509114A Monoclonal antibodies against claudin-18 for treatment of cancer |
| 01/15/2014 | CN103509113A Novel antibodies inhibiting c-MET dimerization, and uses thereof |
| 01/15/2014 | CN103509112A Novel antibodies inhibiting c-MET dimerization, and uses thereof |
| 01/15/2014 | CN103509111A Human anti-KIR antibodies |
| 01/15/2014 | CN103509110A Monoclonal antibodies against claudin-18 for treatment of cancer |
| 01/15/2014 | CN103509109A Method for improving quality of blood serum |
| 01/15/2014 | CN103509108A Method of preparing bombyx mori silk fibroin specific antibody by utilizing characteristic dodecapeptide |
| 01/15/2014 | CN103509107A Method of preparing bombyx mori silk fibroin specific antibody by utilizing characteristic polypeptide |
| 01/15/2014 | CN103509106A Method for extracting chicken egg-yolk antibody |
| 01/15/2014 | CN103509086A Function epitope of botulinum toxin, monoclonal antibody binding to its specificity and applications thereof |
| 01/15/2014 | CN103509068A Amikacin semi-antigen, and preparation method and application thereof |
| 01/15/2014 | CN103508910A Beta-agonist semi-antigen, and preparation method and application thereof |
| 01/15/2014 | CN102732974B Method for constructing phage antibody libraries and CD6-resisting antibody obtained by screening by using phage antibody libraries |
| 01/15/2014 | CN102703388B Anti-human mCRP (monomeric C-reaction protein) monoclonal antibody, hybridoma cell lines and kit |